Novo Nordisk’s CagriSema demonstrates superior weight loss results in REDEFINE 1 trial

Novo Nordisk A/S has unveiled significant findings from its REDEFINE 1 trial, marking a major advancement in the treatment of obesity and overweight conditions. Conducted ... Read More